Medivation is an American biopharmaceutical giant which is based in San Francisco. The company is focused on rapidly developing drugs which help in treating serious diseases with limited treatment possibilities. The corporation is enlisted on NASDAQ stock exchange under the symbol MDVN. It has production facilities based in United States along with many Research and Development bases too. David Hung serves the company as its Chairman and CEO and also leads its R and D department. As of 2015, it is one of the most commercially successful new companies to emerge in the United States.
The corporation is just a year over a decade old and already has become the most sought after pharmaceutical player in the North American continent. It was founded by David Hung in December 2004 as a result of the acquisition of Medivation Neurology, Inc. Since then, it has collaborated with many other companies from the same industry in order to tighten its grip on the American as well as international markets and also to enhance the workings of its R and D department. Recently it was in the news for collaborating with the European pharmaceutical giant Astellas when the U.S. Food and Drug Administration (FDA) approved the result of its joint venture that produced XTANDI (enzalutamide) capsules. This was a major breakthrough for both the entities as is known to be highly successful in treating patients with metastatic castration-resistant prostate cancer. The procedure of the drug is basically applied in post-chemotherapy of the patients.